Drug Profile
TAK 683
Alternative Names: TAK-683Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Takeda
- Developer Millennium
- Class Antineoplastics
- Mechanism of Action KISS1R protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 07 Apr 2009 Phase I development is ongoing in the UK